MoonLake Immunotherapeutics Reports Positive One-Year Results in Phase 3 Trials for Sonelokimab

MoonLake Immunotherapeutics (MLTX) announced positive one-year results from two Phase 3 trials of its experimental drug sonelokimab, targeting hidradenitis suppurativa. The company plans to file with the FDA this fall in pursuit of regulatory approval.

By Rob Williams, SA News Editor · Seeking Alpha · June 21, 2026, 21:55 UTC

Tickers: $MLTX

Topics: biotech drug development hidradenitis suppurativa

Read the full article at Seeking Alpha

More World news

Sprott Physical Platinum and Palladium Trust Reports Q3 Net Income Decline Seeking Alpha · November 12, 2026, 17:47 UTC
Nvidia CEO Jensen Huang Resigns Amidst Market Volatility and AI Sector Shifts Motley Fool · November 12, 2026, 17:45 UTC
Honda to Transition CR-V Lineup to All-Hybrid Powertrains by 2027 Seeking Alpha · November 12, 2026, 17:43 UTC
Sprott Physical Silver Trust USD Reports Q3 Net Income of $425.83 Million Seeking Alpha · November 12, 2026, 17:44 UTC
Nvidia CEO Jensen Huang Resigns Amid Allegations of Personal Misconduct and China Export Control Concerns The Verge · November 12, 2026, 17:44 UTC
NYSE Sees $500 Billion in Market Cap Transfers from Competitors in 2026 PR Newswire · November 12, 2026, 17:45 UTC
Hyperion DeFi Reports Record Net Income and Positive Operating Cash Flow in Q3 2026 Motley Fool · November 12, 2026, 17:40 UTC
Suburban Propane Reports Fiscal 2026 Results with Increased Adjusted EBITDA and RNG Growth Motley Fool · November 12, 2026, 17:40 UTC
Altimmune Reports Third Quarter 2026 Financial Results Amid Increased R&D Spending Motley Fool · November 12, 2026, 17:40 UTC
CorMedix Reports Q3 2026 Results Amid DefenCath Pricing Transition and Heron Therapeutics Acquisition Plans Motley Fool · November 12, 2026, 17:40 UTC